Sirtuin 1 (SirT1) is involved in the pathogenesis of allergic asthma. This study aimed to investigate whether eX-527, a specific SirT1 inhibitor, exerted suppressive effects on allergic airway inflammation in mice submitted to ovalbumin (oVa) inhalation. in addition, this study assessed whether such a protective role was mediated by autophagy suppression though mammalian target of rapamycin (mTor) activation. Female c57Bl/6 mice were sensitized to oVa and eX-527 (10 mg/kg) was administered prior to oVa challenge. The study found that eX-527 reversed oVa-induced airway inflammation, and reduced OVA-induced increases in inflammatory cytokine expression, and total cell and eosinophil counts in bronchoalveolar lavage fluid. In addition, EX-527 enhanced mTor activation, thereby suppressing autophagy in allergic mice. To assess whether EX-527 inhibited airway inflammation in asthma through the mTor-mediated autophagy pathway, rapamycin was administered to mice treated with eX-527 after oVa sensitization. all effects induced by eX-527, including increased phosphorylated-mTor and decreased autophagy, were abrogated by rapamycin treatment. Taken together, the present findings indicated that EX-527 may inhibit allergic airway inflammation by suppressing autophagy, an effect mediated by mTor activation in allergic mice.